Abstract 3629
Background
Programmed death-1 inhibitors (PD-1i) have been approved in the treatment of patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who progressed on or after platinum-containing regimens. More recently, it has been shown that pembrolizumab was superior to the standard EXTREME regimen in first line setting in pts with R/M SCCHN with CPS > 20% and 1% in term of overall survival (OS). We aim in this study to compare the efficacy of immune checkpoint inhibitors (ICI) used as first versus second line in R/M SCCHN to define the best treatment strategy.
Methods
A retrospective study was conducted at 4 French university hospitals. Eligibility criteria were pts treated with ICI for R/M SCCHN as first or second line treatment only and for whom efficacy data were available between September 2014 and March 2019. Clinical and radiological data and outcome were collected from review of medical records.
Results
One hundred ninety two pts were included in this study: 57 pts (30%) received ICI as first line treatment (G1) and 135 pts (70%) as second line setting (G2). Median age at the beginning of ICI was 63 years (range 25-86). All pts were in clinical trials. In G1, ICI was given as monotherapy in 23% of pts and in 66% of pts in G2. The objective response rate (ORR) to ICI in G1 was 17.5% and 17.9% in G2 (p = 0.004). The median duration of response to ICI in G1 was 7.3 months compared to 15.2 months in G2 (p = 0.04). The median progression free survival in G1 was 3.3 months versus 2.7 months in G2 (p = 0.7). The mOS from the beginning of ICI was 12.2 months in G1 versus 11.6 months in G2 (p = 0.7). The mOS from the diagnosis of advanced disease was 15.9 months in G1 versus 22.1 months in G2 (p = 0.11) after a median follow-up of 28.5 months. In G1 38 pts (67%) and 73 pts (53%) in G2 received salvage chemotherapy (SCT) after progression on ICI. The ORR to SCT was 44% in G1 and 34% in G2.
Conclusions
ICI given as second line treatment were associated with similar OS but significant prolonged duration of response. We showed a trend to better OS in the cohort of pts who received ICI in second line setting (22 months).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract
2142 - Low NK Cell Abundance Correlates with High Expression of PD-1 in CD8+ T Cells
Presenter: Moon Hee Lee
Session: Poster Display session 3
Resources:
Abstract
5501 - Tobacco smoking is associated with the immune suppressive microenvironment in head and neck squamous cell carcinoma (HNSCC)
Presenter: Christine Chung
Session: Poster Display session 3
Resources:
Abstract
5726 - Evaluation of Antibody-Dependent Cell Cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy.
Presenter: Francesca Sparano
Session: Poster Display session 3
Resources:
Abstract
2534 - Radiomic Signatures for Identification of Tumors Sensitive to Nivolumab or Docetaxel in Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Presenter: Laurent Dercle
Session: Poster Display session 3
Resources:
Abstract
3366 - Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers
Presenter: FEIYU ZHANG
Session: Poster Display session 3
Resources:
Abstract
2089 - Pathogenesis of Myocarditis Following Treatment with Immune Checkpoint Inhibitors in a Cynomolgus Monkey Model
Presenter: Changhua Ji
Session: Poster Display session 3
Resources:
Abstract
4463 - Effects of dietary restriction in cancer patients receiving irinotecan
Presenter: Ruben Van Eerden
Session: Poster Display session 3
Resources:
Abstract
4841 - Investigating the Link between Burn Injury and Tumorigenesis
Presenter: Lucy Barrett
Session: Poster Display session 3
Resources:
Abstract
4619 - Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in male breast cancer patients
Presenter: Joanna Huszno
Session: Poster Display session 3
Resources:
Abstract